推薦產品
等級
pharmaceutical primary standard
API 家族
interferon
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
運輸包裝
dry ice
儲存溫度
−70°C
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Interferon β-1a EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Normand E Allaire et al.
BMC research notes, 6, 8-8 (2013-01-08)
Clinical trials offer a unique opportunity to study human disease and response to therapy in a highly controlled setting. The application of high-throughput expression profiling to peripheral blood from clinical trial subjects could facilitate the identification of transcripts that function
F Wild
Der Nervenarzt, 84(2), 202-208 (2012-12-18)
For persons covered by statutory health insurance (SHI) an increase in the number of defined daily doses (DDD) for pharmaceuticals to treat multiple sclerosis (MS) is known but so far there has been no comparable survey for private health insurance
Diego Cadavid et al.
PloS one, 8(1), e53297-e53297 (2013-01-12)
There is an unmet need for disease-modifying therapies to improve ambulatory function in disabled subjects with multiple sclerosis. Assess the effects of natalizumab on ambulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS).
Tae Ikeda et al.
No to hattatsu = Brain and development, 45(1), 49-52 (2013-04-19)
We report a case of a 15-year-old girl with relapsing-remitting multiple sclerosis (MS) who received cyclophosphamide pulse therapy. At the age of 5 years, she displayed symptoms such as headache and unconsciousness after varicella infection as the first episode of
Jeffrey A Cohen et al.
Lancet (London, England), 380(9856), 1819-1828 (2012-11-06)
The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務